Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A randomized, double-blind, placebo-controlled, adaptive, seamless phase I / II clinical study of the safety and immunogenicity of a recombinant viral vector AAV5-RBD-S vaccine for the prevention of coronavirus infection (COVID-19)
Epistemonikos ID: 8bd5f5935c72ded113e3d5c3ce9345eb9ba026b7
First added on: Sep 09, 2021